CEST AND T1RHO MRI OF LIVER FIBROSIS

肝纤维化的 CEST 和 T1RHO MRI

• 批准号: 8361974
• 负责人: Kewen Cai
• 金额: $ 3.84万
• 依托单位: UNIVERSITY OF PENNSYLVANIA
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-06-01 至 2012-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8361974
• 关键词: Adult; Animal Model; Cessation of life; Chronic; Contrast Media; Detection; Diagnosis; Fatty acid glycerol esters; Funding; Gold; Grant; Hepatic; Human; Lesion; Liver; Liver Fibrosis; Liver diseases; Magnetic Resonance; Magnetic Resonance Imaging; Monitor; National Center for Research Resources; Pathology; Patients; Performance; Principal Investigator; Procedures; Reproducibility; Research; Research Infrastructure; Resources; Sampling; Source; Techniques; United States; United States National Institutes of Health; Weight; advanced system; cost; improved; liver biopsy; optical imaging

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. While liver disease is currently ranked as the seventh leading cause of adult death in the United States, the gold standard to diagnose and monitor the progress of patients afflicted with hepatic pathologies remains limited to liver biopsy. Liver biopsies can be associated with sampling variability, poor reproducibility and major complications, rendering it essential to develop non-invasive techniques able to diagnose different liver conditions. With the advent of high performance magnetic resonance (MR) systems and advanced sequences, MRI shows potential for improved and non-invasive assessment of liver disease. Fast spin echo or single shot techniques, often combined with fat suppression, are the most common T2 weighted sequences used in liver MRI procedures. Liver MRI is highly dependent on the administration of contrast agents, especially when detection and characterization of focal lesions are the issues. Currently, there is no single MRI technique that is optimal for detecting the different liver pathologies. The objective of this project is to develop CEST and T1p MRI techniques for monitoring the progression of chronic liver diseases and liver fibrosis in human and animal models.

这个子项目是利用资源的许多研究子项目之一。 由NIH/NCRR资助的中心拨款提供。对子项目的主要支持 子项目的首席调查员可能是由其他来源提供的， 包括美国国立卫生研究院的其他来源。为子项目列出的总成本可能 表示该子项目使用的中心基础设施的估计数量， 不是由NCRR赠款提供给次级项目或次级项目工作人员的直接资金。 目前，肝病是美国成人死亡的第七大原因 国家，诊断和监测肝病患者进展的金标准 病理检查仍仅限于肝脏活检。肝活组织检查可以与采样变异性有关， 重复性差和严重并发症，因此开发非侵入性技术是必要的 能够诊断不同的肝脏状况。随着高性能磁共振技术的出现 (MR)系统和高级序列，MRI显示出改进和非侵入性的潜力 对肝病的评估。快速自旋回波或单次激发技术，通常与FAT结合使用 抑制，是肝脏MRI程序中最常见的T2加权序列。肝脏MRI 高度依赖于造影剂的给药，特别是当检测和 局灶性病变的特征是问题。目前，还没有单一的MRI技术可以 最适合检测不同的肝脏病变。本项目的目标是开发CEST 和T1p磁共振技术监测人和动物慢性肝病和肝纤维化的进展 模特们。